|
Cell line
|
ER
|
PR
|
HER2
|
BRCA1
|
BD-Lmetagene value
|
|---|
|
HCC1143
|
-
|
-
|
-
|
NA
|
207.2555
|
|
MDAMB415
|
+
|
-
|
-
|
wt/-
|
208.6937
|
|
HCC1937
|
-
|
-
|
-
|
m/-
|
226.181
|
|
BT20
|
-
|
-
|
-
|
wt/-
|
227.6686
|
|
MDAMB468
|
-
|
-
|
-
|
wt/-
|
260.2652
|
|
BT474
|
+
|
+
|
+
|
wt/-
|
261.2111
|
|
HCC1428
|
+
|
+
|
-
|
NA
|
265.375
|
|
MDAMB134VI
|
+
|
-
|
-
|
wt/wt
|
267.9736
|
|
SKBR3
|
-
|
-
|
+
|
wt/-
|
277.6819
|
|
MCF10A
|
-
|
-
|
-
|
NA
|
285.3522
|
|
HCC1954
|
-
|
-
|
+
|
NA
|
300.0448
|
|
HCC1500
|
-
|
-
|
-
|
NA
|
300.3202
|
- Breast cancer cell lines selected for pharmacological inhibition evaluation. BD-L metagene values for the cell lines, as calculated from the Neve et al. [21] data set, are listed by increasing value. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) protein expression status are indicated. If known, the BRCA1 mutational status is noted (NA: not available).
